Other Peptides
Specialized peptides and compounds that span multiple categories or have unique mechanisms of action.
This category includes peptides with unique mechanisms of action or those that don't fit neatly into other categories. These compounds may have diverse research applications spanning multiple therapeutic areas.
225Ac-DOTA-LM3
Actinium-225-DOTA-LM3, 225Ac-DOTA-JR11, Alpha-PRRT +1 more
An alpha-emitting radiolabeled somatostatin receptor antagonist for peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Unlike conventional beta-emitting Lu-177 therapies and SSTR agonists, 225Ac-DOTA-LM3 combines the higher cell-killing power of alpha particles with antagonist binding for enhanced tumor targeting. Clinical stage investigational therapy showing promise in Lu-177-refractory patients.
Bronchogen
AEDL, Ala-Glu-Asp-Leu, Bronchial tetrapeptide +1 more
A synthetic tetrapeptide (Ala-Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for bronchial and respiratory tissue support. Claimed to modulate bronchial epithelium gene expression and provide respiratory protective effects. No Western clinical validation; all evidence from Russian bioregulator research.
BT5528
Bicycle Toxin Conjugate 5528, EphA2-BTC
A first-in-class Bicycle Toxin Conjugate (BTC) targeting EphA2-expressing tumors, developed by Bicycle Therapeutics. Combines a constrained bicyclic peptide targeting moiety with the cytotoxic payload MMAE. Phase 1/2 dose expansion ongoing with 67% ORR reported in EphA2-positive urothelial cancer patients.
Cardiogen
AED, Ala-Glu-Asp, Cardiac tripeptide
A synthetic tripeptide (Ala-Glu-Asp) developed by Russian scientist Vladimir Khavinson for cardiac tissue support. Claimed to target cardiomyocyte gene expression and provide cardioprotective effects. No Western clinical validation exists; evidence limited to Russian preclinical and observational studies.
Chonluten
EDG-GI, Glu-Asp-Gly (GI), GI tract tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Gly) developed by Vladimir Khavinson for gastrointestinal tissue support. Shares the same amino acid sequence as Kristagen but is marketed for digestive system rather than immune function. Limited to Russian studies with no Western validation or clinical trials.
EVX-01
EVX01, Evaxion EVX-01, AI-Immunology Neoantigen Vaccine
A personalized neoantigen peptide vaccine developed by Evaxion Biotech using AI-driven neoantigen prediction. Phase 1 data in melanoma showed 67% overall response rate when combined with anti-PD-1 therapy, with neoantigen-specific T-cell responses detected in all patients. Distinct from mRNA-based approaches like mRNA-4157.
Livagen
KED, Lys-Glu-Asp, Hepatogen
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support liver function and modulate hepatic gene expression. Minimal Western validation exists; all research originates from Russian institutions with no controlled human clinical trials.
Melanotan II
MT-II, MT-2
A non-selective melanocortin receptor agonist known for tanning effects. Not approved by any regulatory agency; associated with significant safety concerns including melanoma risk and systemic toxicity.
Melanotan-1
Afamelanotide, Scenesse, NDP-MSH +4 more
An FDA-approved synthetic analog of alpha-MSH that selectively activates MC1R to stimulate eumelanin production. Approved as Scenesse for erythropoietic protoporphyria (EPP), making it the first and only treatment for this rare photosensitivity disorder.
mRNA-4157/V940
V940, mRNA-4157, INTerpath vaccine
A personalized mRNA cancer vaccine encoding up to 34 patient-specific neoantigens, developed jointly by Moderna and Merck. Designed for use in combination with pembrolizumab (Keytruda) for adjuvant treatment of resected high-risk melanoma and other solid tumors. Phase 2b KEYNOTE-942 demonstrated 44-50% reduction in recurrence or death. FDA Breakthrough Therapy designation granted. Multiple Phase 3 trials (INTerpath) ongoing.
Ovagen
EDL, Glu-Asp-Leu, Hepatic tripeptide +1 more
A synthetic tripeptide (Glu-Asp-Leu) developed by Russian scientist Vladimir Khavinson for liver support. Part of the peptide bioregulation framework claiming tissue-specific gene regulation. No Western clinical validation exists.
Pancragen
KEDW, Lys-Glu-Asp-Trp, Pancreatic tetrapeptide +1 more
A synthetic tetrapeptide (Lys-Glu-Asp-Trp) developed by Russian scientist Vladimir Khavinson for pancreatic support. Claimed to modulate pancreatic tissue gene expression and support insulin-producing beta cell function. No Western clinical validation.
Retinalamin
Retinal peptide complex, Eye peptide, Retina bioregulator
A peptide complex extracted from bovine or porcine retinal tissue, developed by Russian scientist Vladimir Khavinson for ophthalmologic applications. Registered as a drug in Russia for retinal dystrophy and age-related macular degeneration. Very limited Western validation exists.
Stamakort
Gastric peptide, Stomach bioregulator, Gastric mucosa peptide
A peptide bioregulator developed by Russian scientist Vladimir Khavinson for gastric mucosa support. Claimed to modulate stomach lining gene expression and support digestive function. No Western clinical validation exists.
Sulanemadlin
ALRN-6924, MP-4897
First-in-class stapled alpha-helical peptide and dual MDM2/MDMX inhibitor that reactivates wild-type p53 tumor suppressor function. Phase 1/2 trials demonstrated 59% disease control rate with notably low hematologic toxicity compared to MDM2-only inhibitors. Novel chemoprotection application being developed for retinoblastoma with Advancium Biosciences partnership.
Suprefort
Pancreatic cytamin, Pancreas peptides, A-11 pancreatic peptides
A cytamin-class peptide supplement derived from pancreatic tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for pancreatic support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Svetinorm
Liver cytamin, Hepatic peptides, A-4 liver peptides
A cytamin-class peptide supplement derived from liver tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for liver health support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Ventfort
Vascular cytamin, Blood vessel peptides, A-14 vascular peptides
A cytamin-class peptide supplement derived from blood vessel tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for vascular health support. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Vesugen
KED-vascular, Lys-Glu-Asp (vascular), Vascular tripeptide
A synthetic tripeptide (Lys-Glu-Asp) developed by Russian scientist Vladimir Khavinson, claimed to support vascular health by modulating endothelial gene expression. Russian studies suggest cardiovascular protective effects. No Western clinical validation or regulatory approval anywhere.
Zelenectide Pevedotin
BT8009, Bicycle Drug Conjugate BT8009
A first-in-class Bicycle Drug Conjugate (BDC) targeting Nectin-4 for solid tumors, developed by Bicycle Therapeutics. Demonstrates 45% overall response rate in metastatic urothelial cancer with a novel bicyclic peptide platform approximately 40x smaller than traditional antibody-drug conjugates. Phase 2/3 Duravelo-2 registrational trial ongoing.
About This Category
Peptides in this category may target unique biological pathways or have multi-modal effects that don't fit within a single classification. Each dossier provides detailed evidence analysis specific to the compound's primary research applications.